Table 2: Non-Opioid Drugs for Pain Management
|
DRUG |
STARTING ORAL DOSE |
SPECIFIC INDICATIONS |
POTENTIAL ADVERSE EFFECTS |
PRECAUTIONS AND RECOMMENDATIONS |
|
Corticosteroids, e.g., prednisone |
2.5-5 mg daily |
Inflammatory diseases |
Hyperglycemia, osteo-penia, Cushingâs |
Avoid high dose for long-term use |
|
Tricyclic Antidepressants, e.g. amitriptyline, desipramine, doxepin, imipramine, nortriptyline |
10 mg HS |
Neuropathic pain, sleep disturbance |
Increased sensitivity to side effects, especially anticholinergic effects |
Monitor carefully for anticholinergic side effects; desipramine may be as effective as amitriptyline with fewer side effects; start at lowest available dose (10 mg) and titrate HS dose upward by 10 mg every 3-5 days; schedule frequent follow-up visits |
|
Anticonvulsants |
|
Neuropathic pain |
|
|
|
Clonazapam |
0.25-0.5 mg |
|
Sedation, balance disturbance |
|
|
Carbamazapine |
100 mg |
Trigeminal neuralgia |
Somnolence, ataxia, dizziness, leukopenia, thrombocytopenia, rarely aplastic anemia |
Start at 100 mg qd, increase slowly bid, 200 mg qd, then bid; check LFTs, CBC, Cr/BUN at baseline; CBC at 2 and 8 weeks |
|
Gabapentin |
100 mg |
|
Ataxia, ankle swelling, nausea |
Appears to have less serious side effects than carbamazapine; titrate slowly to effective dose vs. side effects (up to 35 mg/kg/day) |
|
Antiarrhythmics, e.g., mexiletine |
150 mg |
Neuropathic pain |
Tremor, dizziness, ataxia, rarely blood dyscrasias, hepatotoxicity |
Avoid use in patients with exigent or potential for conduction defects or block; start with low dose and titrate slowly to 10-15 mg/kg/day tid dosing; recommend initial and follow-up EKGs |
|
Other Agents |
|
|
|
|
|
Baclofen |
5 mg |
Neuropathic pain, muscle spasms |
Sedation, weakness, ataxia |
Monitor for urinary dysfunction; discontinue via tapering to avoid possibility of CNS irritability withdrawal seizures; titrate slowly up to 1 mg/kg day tid dosing balancing therapeutic effects vs. toxicity |